Research
Hormonal
Prescription omega-3s (4 g/d EPA-only) reduce major adverse cardiovascular events by 25% in high-risk patients with hypertriglyceridemia who are already taking statins.
If you are at high risk for heart disease and have high triglycerides, ask your doctor about adding prescription EPA-only omega-3s (like Vascepa) to your statin. The REDUCE-IT trial showed this combination reduced major heart events by 25% compared to placebo.
StrongSupportsVERY_HIGH confidence
The use of n-3 FA (4 g/d) for improving atherosclerotic cardiovascular disease risk in patients with hypertriglyceridemia is supported by a 25% reduction in major adverse cardiovascular events in REDUCE-IT (Reduction of Cardiovascular Events With EPA Intervention Trial), a randomized placebo-controlled trial of EPA-only in high-risk patients treated with a statin.
Why this rating
Based on a large, randomized, placebo-controlled trial (REDUCE-IT).
Source
Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
Ann C. Skulas‐Ray et al. · Circulation · 2019
clinical_guidelineCited 465×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →